Biogen has recently changed the wording on the Touch Pamphlet for Tysabri and it now reads:
Because of the chance of getting PML, TYSABRI
is generally recommended for patients that have
not been helped enough by, or cannot tolerate
other treatments for MS
Here's the link -
http://www.fda.gov/ohrms/dockets/ac/...n-Addendum.pdf